HK Stock Market Move | Yimingangke (01541) rose more than 3%. The MM0306 clinical study is currently actively recruiting and observing.

Yimingangke (01541) is up over 3%, at the time of writing, up by 3.56% to HK$7.53, with a turnover of HK$7.5517 million. In terms of news, Yimingangke has announced that the Ib/IIa phase clinical trial of IMM0306 in combination with lenalidomide for the treatment of chronic lymphocytic lymphoma has recruited a total of 27 evaluable patients (25 follicular lymphoma (FL) patients and two marginal zone lymphoma (MZL) patients) on October 26. As of October 26, the overall response rate (ORR) and complete response rate (CRR) in 25 evaluable R/R FL patients were 84% and 40% respectively, while the overall response rate in two evaluable R/R MZL patients reached 100%, indicating a prominent treatment efficacy signal. The study is currently actively recruiting and observing. IMM0306 is a dual-specificity molecule targeting cluster of differentiation 47 (CD47) and cluster of differentiation 20 (CD20), and is the world's first CD47 and CD20 dual-targeting dual-specificity molecule to enter clinical stage. By enhancing antibody-dependent cellular phagocytosis (ADCP) and antibody-dependent cellular cytotoxicity (ADCC), IMM0306 can simultaneously bind to CD47 and CD20 expressed on malignant B cells, with higher affinity for CD20 than CD47, thus improving treatment efficacy.